Literature DB >> 18579696

Novel protective antigens expressed by Trypanosoma cruzi amastigotes provide immunity to mice highly susceptible to Chagas' disease.

Eduardo L V Silveira1, Carla Claser, Filipe A B Haolla, Luiz G Zanella, Mauricio M Rodrigues.   

Abstract

Earlier studies have demonstrated in A/Sn mice highly susceptible to Chagas' disease protective immunity against lethal Trypanosoma cruzi infection elicited by vaccination with an open reading frame (ORF) expressed by amastigotes. In our experiments, we used this mouse model to search for other amastigote-expressed ORFs with a similar property. Fourteen ORFs previously determined to be expressed in this developmental stage were individually inserted into a eukaryotic expression vector containing a nucleotide sequence that encoded a mammalian secretory signal peptide. Immunization with 13 of the 14 ORFs induced specific antibodies which recognized the amastigotes. Three of those immune sera also reacted with trypomastigotes and epimastigotes. After a lethal challenge with Y strain trypomastigotes, the vast majority of plasmid-injected mice succumbed to infection. In some cases, a significant delay in mortality was observed. Only two of these ORFs provided protective immunity against the otherwise lethal infection caused by trypomastigotes of the Y or Colombia strain. These ORFs encode members of the trans-sialidase family of surface antigens related to the previously described protective antigen amastigote surface protein 2 (ASP-2). Nevertheless, at the level of antibody recognition, no cross-reactivity was observed between the ORFs and the previously described ASP-2 from the Y strain. In immunofluorescence analyses, we observed the presence of epitopes related to both proteins expressed by amastigotes of seven different strains. In conclusion, our approach allowed us to successfully identify two novel protective ORFs which we consider interesting for future studies on the immune response to Chagas' disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18579696      PMCID: PMC2519309          DOI: 10.1128/CVI.00142-08

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  46 in total

1.  Comparative genomics of trypanosomatid parasitic protozoa.

Authors:  Najib M El-Sayed; Peter J Myler; Gaëlle Blandin; Matthew Berriman; Jonathan Crabtree; Gautam Aggarwal; Elisabet Caler; Hubert Renauld; Elizabeth A Worthey; Christiane Hertz-Fowler; Elodie Ghedin; Christopher Peacock; Daniella C Bartholomeu; Brian J Haas; Anh-Nhi Tran; Jennifer R Wortman; U Cecilia M Alsmark; Samuel Angiuoli; Atashi Anupama; Jonathan Badger; Frederic Bringaud; Eithon Cadag; Jane M Carlton; Gustavo C Cerqueira; Todd Creasy; Arthur L Delcher; Appolinaire Djikeng; T Martin Embley; Christopher Hauser; Alasdair C Ivens; Sarah K Kummerfeld; Jose B Pereira-Leal; Daniel Nilsson; Jeremy Peterson; Steven L Salzberg; Joshua Shallom; Joana C Silva; Jaideep Sundaram; Scott Westenberger; Owen White; Sara E Melville; John E Donelson; Björn Andersson; Kenneth D Stuart; Neil Hall
Journal:  Science       Date:  2005-07-15       Impact factor: 47.728

2.  Distinct kinetics of effector CD8+ cytotoxic T cells after infection with Trypanosoma cruzi in naive or vaccinated mice.

Authors:  Fanny Tzelepis; Bruna C G de Alencar; Marcus L O Penido; Ricardo T Gazzinelli; Pedro M Persechini; Mauricio M Rodrigues
Journal:  Infect Immun       Date:  2006-04       Impact factor: 3.441

3.  Vaccination with trypomastigote surface antigen 1-encoding plasmid DNA confers protection against lethal Trypanosoma cruzi infection.

Authors:  B Wizel; N Garg; R L Tarleton
Journal:  Infect Immun       Date:  1998-11       Impact factor: 3.441

4.  Type 1 immunity provides both optimal mucosal and systemic protection against a mucosally invasive, intracellular pathogen.

Authors:  Daniel F Hoft; Chris S Eickhoff
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

5.  Molecular characterization and transcription of the histone H2B gene from the protozoan parasite Trypanosoma cruzi.

Authors:  J A García-Salcedo; J L Oliver; R P Stock; A González
Journal:  Mol Microbiol       Date:  1994-09       Impact factor: 3.501

6.  Predominance of CD4 Th1 and CD8 Tc1 cells revealed by characterization of the cellular immune response generated by immunization with a DNA vaccine containing a Trypanosoma cruzi gene.

Authors:  M M Rodrigues; M Ribeirão; V Pereira-Chioccola; L Renia; F Costa
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

Review 7.  Parasite persistence in the aetiology of Chagas disease.

Authors:  R L Tarleton
Journal:  Int J Parasitol       Date:  2001-05-01       Impact factor: 3.981

8.  Genetic immunization elicits antigen-specific protective immune responses and decreases disease severity in Trypanosoma cruzi infection.

Authors:  Nisha Garg; Rick L Tarleton
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

Review 9.  Trypanosoma cruzi infection from the view of CD8+ T cell immunity--an infection model for developing T cell vaccine.

Authors:  Yasushi Miyahira
Journal:  Parasitol Int       Date:  2007-08-01       Impact factor: 2.230

10.  DNA Vaccines against Protozoan Parasites: Advances and Challenges.

Authors:  Eric Dumonteil
Journal:  J Biomed Biotechnol       Date:  2007
View more
  8 in total

1.  Perforin and gamma interferon expression are required for CD4+ and CD8+ T-cell-dependent protective immunity against a human parasite, Trypanosoma cruzi, elicited by heterologous plasmid DNA prime-recombinant adenovirus 5 boost vaccination.

Authors:  Bruna C G de Alencar; Pedro M Persechini; Filipe A Haolla; Gabriel de Oliveira; Jaline C Silverio; Joseli Lannes-Vieira; Alexandre V Machado; Ricardo T Gazzinelli; Oscar Bruna-Romero; Mauricio M Rodrigues
Journal:  Infect Immun       Date:  2009-08-03       Impact factor: 3.441

2.  Testing the efficacy of a multi-component DNA-prime/DNA-boost vaccine against Trypanosoma cruzi infection in dogs.

Authors:  José E Aparicio-Burgos; Laucel Ochoa-García; José Antonio Zepeda-Escobar; Shivali Gupta; Monisha Dhiman; José Simón Martínez; Roberto Montes de Oca-Jiménez; Margarita Val Arreola; Alberto Barbabosa-Pliego; Juan C Vázquez-Chagoyán; Nisha Jain Garg
Journal:  PLoS Negl Trop Dis       Date:  2011-05-17

3.  Biological and immunological characterization of recombinant Yellow Fever 17D viruses expressing a Trypanosoma cruzi Amastigote Surface Protein-2 CD8+ T cell epitope at two distinct regions of the genome.

Authors:  Raquel T Nogueira; Alanderson R Nogueira; Mirian C S Pereira; Maurício M Rodrigues; Ricardo Galler; Myrna C Bonaldo
Journal:  Virol J       Date:  2011-03-18       Impact factor: 4.099

4.  Recombinant Enolase of Trypanosoma cruzi as a Novel Vaccine Candidate against Chagas Disease in a Mouse Model of Acute Infection.

Authors:  Minerva Arce-Fonseca; María Cristina González-Vázquez; Olivia Rodríguez-Morales; Verónica Graullera-Rivera; Alberto Aranda-Fraustro; Pedro A Reyes; Alejandro Carabarin-Lima; José Luis Rosales-Encina
Journal:  J Immunol Res       Date:  2018-05-07       Impact factor: 4.818

5.  Trypanosoma cruzi SSP4 Amastigote Protein Induces Expression of Immunoregulatory and Immunosuppressive Molecules in Peripheral Blood Mononuclear Cells.

Authors:  Yadira Morán-Utrera; Aracely López-Monteon; José Luis Rosales-Encina; Enrique Méndez-Bolaina; Angel Ramos-Ligonio
Journal:  J Trop Med       Date:  2012-11-01

6.  Recombinant yellow fever viruses elicit CD8+ T cell responses and protective immunity against Trypanosoma cruzi.

Authors:  Raquel Tayar Nogueira; Alanderson Rocha Nogueira; Mirian Claudia Souza Pereira; Maurício Martins Rodrigues; Patrícia Cristina da Costa Neves; Ricardo Galler; Myrna Cristina Bonaldo
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

Review 7.  CD8(+) T cell-mediated immunity during Trypanosoma cruzi infection: a path for vaccine development?

Authors:  Fernando Dos Santos Virgilio; Camila Pontes; Mariana Ribeiro Dominguez; Jonatan Ersching; Mauricio Martins Rodrigues; José Ronnie Vasconcelos
Journal:  Mediators Inflamm       Date:  2014-07-01       Impact factor: 4.711

8.  A Novel Vaccine Approach for Chagas Disease Using Rare Adenovirus Serotype 48 Vectors.

Authors:  Anitra L Farrow; Binghao J Peng; Linlin Gu; Alexandre Krendelchtchikov; Qiana L Matthews
Journal:  Viruses       Date:  2016-03-10       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.